Double-Drug attack on Hard-to-Treat prostate cancer begins human testing

NCT ID NCT07082920

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pasritamig (JNJ-78278343) and ARX517 (JNJ-95298177)
What this could lead to: If successful, this could lead to a new combination treatment option for advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is an early phase 1 trial, so safety and dosing are still being figured out. The drugs may cause serious side effects like cytokine release syndrome, and there is no guarantee they will shrink tumors or extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Royal Marsden Hospital (Sutton)
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Christie Nhs Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.